Loading…

COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population

The Bacillus Calmette-Guérin (BCG) is a well-known vaccine with almost a century of use, with the apparent capability to improve cytokine production and epigenetics changes that could develop a better response to pathogens. It has been postulated that BCG protection against SARS-CoV-2 has a potentia...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-01, Vol.9 (2), p.91
Main Authors: Garzon-Chavez, Daniel, Rivas-Condo, Jackson, Echeverria, Adriana, Mozo, Jhoanna, Quentin, Emmanuelle, Reyes, Jorge, Teran, Enrique
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c487t-7aa62450cf92fb9bde119e912410d04cda15c3382daaa13e56b566c0e7e9660d3
cites cdi_FETCH-LOGICAL-c487t-7aa62450cf92fb9bde119e912410d04cda15c3382daaa13e56b566c0e7e9660d3
container_end_page
container_issue 2
container_start_page 91
container_title Vaccines (Basel)
container_volume 9
creator Garzon-Chavez, Daniel
Rivas-Condo, Jackson
Echeverria, Adriana
Mozo, Jhoanna
Quentin, Emmanuelle
Reyes, Jorge
Teran, Enrique
description The Bacillus Calmette-Guérin (BCG) is a well-known vaccine with almost a century of use, with the apparent capability to improve cytokine production and epigenetics changes that could develop a better response to pathogens. It has been postulated that BCG protection against SARS-CoV-2 has a potential role in the pandemic, through the presence of homologous amino acid sequences. To identify a possible link between BCG vaccination coverage and COVID-19 cases, we used official epidemic data and Ecuadorian Ministry of Health and Pan American Health Organization vaccination information. BCG information before 1979 was available only at a national level. Therefore, projections based on the last 20 years were performed, to compare by specific geographic units. We used a Mann-Kendall test to identify BCG coverage variations, and mapping was conducted with a free geographic information system (QGIS). Nine provinces where BCG vaccine coverage was lower than 74.25% show a significant statistical association (χ Pearson's = 4.800, df = 1, = 0.028), with a higher prevalence of cases for people aged 50 to 64 years than in younger people aged 20 to 49 years. Despite the availability of BCG vaccination data and the mathematical models needed to compare these data with COVID-19 cases, our results show that, in geographic areas where BCG coverage was low, 50% presented a high prevalence of COVID-19 cases that were young; thus, low-coverage years were more affected.
doi_str_mv 10.3390/vaccines9020091
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2bd651de822b4603b280ee90deb85938</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2bd651de822b4603b280ee90deb85938</doaj_id><sourcerecordid>2484212039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-7aa62450cf92fb9bde119e912410d04cda15c3382daaa13e56b566c0e7e9660d3</originalsourceid><addsrcrecordid>eNpdkk1P3DAQQC1UBGjLubfKUi-9pPgjceJLpTaldCUkOADqzZrYk8WrrL11kpX675vNUgScbHmen8czQ8gHzr5IqdnFDqz1AXvNBGOaH5EzwUqVSS1_v3uxPyXnfb9mbM_ISpUn5FTKgkul5Rm5r28elj8yrukytGgHHwOF4Ohtwp2PY0-_11f0YX4I5mAdd5hghdQHOjwivbQjuJg8BHobt2M3U-_JcQtdj-dP64Lc_7y8q39l1zdXy_rbdWbzqhyyEkCJvGC21aJtdOOQc42ai5wzx3LrgBdWyko4AOASC9UUSlmGJWqlmJMLsjx4XYS12Sa_gfTXRPBmPohpZSAN3nZoRONUwR1WQjS5YrIRFUPUzGFTFVpWk-vrwbUdmw06i2FI0L2Svo4E_2hWcWfKOWE1CT4_CVL8M2I_mI3vLXYdBJwqaUReyYpPjeMT-ukNuo5jClOp9lQuuGBT5xbk4kDZFPs-YfucDGdmPwHmzQRMNz6-_MMz_7_f8h84FKyb</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2484212039</pqid></control><display><type>article</type><title>COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Garzon-Chavez, Daniel ; Rivas-Condo, Jackson ; Echeverria, Adriana ; Mozo, Jhoanna ; Quentin, Emmanuelle ; Reyes, Jorge ; Teran, Enrique</creator><creatorcontrib>Garzon-Chavez, Daniel ; Rivas-Condo, Jackson ; Echeverria, Adriana ; Mozo, Jhoanna ; Quentin, Emmanuelle ; Reyes, Jorge ; Teran, Enrique</creatorcontrib><description>The Bacillus Calmette-Guérin (BCG) is a well-known vaccine with almost a century of use, with the apparent capability to improve cytokine production and epigenetics changes that could develop a better response to pathogens. It has been postulated that BCG protection against SARS-CoV-2 has a potential role in the pandemic, through the presence of homologous amino acid sequences. To identify a possible link between BCG vaccination coverage and COVID-19 cases, we used official epidemic data and Ecuadorian Ministry of Health and Pan American Health Organization vaccination information. BCG information before 1979 was available only at a national level. Therefore, projections based on the last 20 years were performed, to compare by specific geographic units. We used a Mann-Kendall test to identify BCG coverage variations, and mapping was conducted with a free geographic information system (QGIS). Nine provinces where BCG vaccine coverage was lower than 74.25% show a significant statistical association (χ Pearson's = 4.800, df = 1, = 0.028), with a higher prevalence of cases for people aged 50 to 64 years than in younger people aged 20 to 49 years. Despite the availability of BCG vaccination data and the mathematical models needed to compare these data with COVID-19 cases, our results show that, in geographic areas where BCG coverage was low, 50% presented a high prevalence of COVID-19 cases that were young; thus, low-coverage years were more affected.</description><identifier>ISSN: 2076-393X</identifier><identifier>EISSN: 2076-393X</identifier><identifier>DOI: 10.3390/vaccines9020091</identifier><identifier>PMID: 33513693</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Amino acids ; Bacillus Calmette-Guerin vaccine ; BCG ; BCG vaccine ; BCG vaccine coverage ; Chi-square test ; Coronaviruses ; COVID-19 ; Cytokines ; Disease transmission ; Ecuador ; Epigenetics ; Geographic information systems ; Granulocytes ; Homology ; Mathematical models ; Pandemics ; Provinces ; Regions ; Remote sensing ; Sequences ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Statistical tests ; Vaccination ; Vaccines ; Viral diseases</subject><ispartof>Vaccines (Basel), 2021-01, Vol.9 (2), p.91</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-7aa62450cf92fb9bde119e912410d04cda15c3382daaa13e56b566c0e7e9660d3</citedby><cites>FETCH-LOGICAL-c487t-7aa62450cf92fb9bde119e912410d04cda15c3382daaa13e56b566c0e7e9660d3</cites><orcidid>0000-0002-5215-164X ; 0000-0001-5600-2361 ; 0000-0001-6979-5655</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2484212039/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2484212039?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,36992,44569,53770,53772,74873</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33513693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garzon-Chavez, Daniel</creatorcontrib><creatorcontrib>Rivas-Condo, Jackson</creatorcontrib><creatorcontrib>Echeverria, Adriana</creatorcontrib><creatorcontrib>Mozo, Jhoanna</creatorcontrib><creatorcontrib>Quentin, Emmanuelle</creatorcontrib><creatorcontrib>Reyes, Jorge</creatorcontrib><creatorcontrib>Teran, Enrique</creatorcontrib><title>COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population</title><title>Vaccines (Basel)</title><addtitle>Vaccines (Basel)</addtitle><description>The Bacillus Calmette-Guérin (BCG) is a well-known vaccine with almost a century of use, with the apparent capability to improve cytokine production and epigenetics changes that could develop a better response to pathogens. It has been postulated that BCG protection against SARS-CoV-2 has a potential role in the pandemic, through the presence of homologous amino acid sequences. To identify a possible link between BCG vaccination coverage and COVID-19 cases, we used official epidemic data and Ecuadorian Ministry of Health and Pan American Health Organization vaccination information. BCG information before 1979 was available only at a national level. Therefore, projections based on the last 20 years were performed, to compare by specific geographic units. We used a Mann-Kendall test to identify BCG coverage variations, and mapping was conducted with a free geographic information system (QGIS). Nine provinces where BCG vaccine coverage was lower than 74.25% show a significant statistical association (χ Pearson's = 4.800, df = 1, = 0.028), with a higher prevalence of cases for people aged 50 to 64 years than in younger people aged 20 to 49 years. Despite the availability of BCG vaccination data and the mathematical models needed to compare these data with COVID-19 cases, our results show that, in geographic areas where BCG coverage was low, 50% presented a high prevalence of COVID-19 cases that were young; thus, low-coverage years were more affected.</description><subject>Age</subject><subject>Amino acids</subject><subject>Bacillus Calmette-Guerin vaccine</subject><subject>BCG</subject><subject>BCG vaccine</subject><subject>BCG vaccine coverage</subject><subject>Chi-square test</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytokines</subject><subject>Disease transmission</subject><subject>Ecuador</subject><subject>Epigenetics</subject><subject>Geographic information systems</subject><subject>Granulocytes</subject><subject>Homology</subject><subject>Mathematical models</subject><subject>Pandemics</subject><subject>Provinces</subject><subject>Regions</subject><subject>Remote sensing</subject><subject>Sequences</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Statistical tests</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>2076-393X</issn><issn>2076-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1P3DAQQC1UBGjLubfKUi-9pPgjceJLpTaldCUkOADqzZrYk8WrrL11kpX675vNUgScbHmen8czQ8gHzr5IqdnFDqz1AXvNBGOaH5EzwUqVSS1_v3uxPyXnfb9mbM_ISpUn5FTKgkul5Rm5r28elj8yrukytGgHHwOF4Ohtwp2PY0-_11f0YX4I5mAdd5hghdQHOjwivbQjuJg8BHobt2M3U-_JcQtdj-dP64Lc_7y8q39l1zdXy_rbdWbzqhyyEkCJvGC21aJtdOOQc42ai5wzx3LrgBdWyko4AOASC9UUSlmGJWqlmJMLsjx4XYS12Sa_gfTXRPBmPohpZSAN3nZoRONUwR1WQjS5YrIRFUPUzGFTFVpWk-vrwbUdmw06i2FI0L2Svo4E_2hWcWfKOWE1CT4_CVL8M2I_mI3vLXYdBJwqaUReyYpPjeMT-ukNuo5jClOp9lQuuGBT5xbk4kDZFPs-YfucDGdmPwHmzQRMNz6-_MMz_7_f8h84FKyb</recordid><startdate>20210127</startdate><enddate>20210127</enddate><creator>Garzon-Chavez, Daniel</creator><creator>Rivas-Condo, Jackson</creator><creator>Echeverria, Adriana</creator><creator>Mozo, Jhoanna</creator><creator>Quentin, Emmanuelle</creator><creator>Reyes, Jorge</creator><creator>Teran, Enrique</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5215-164X</orcidid><orcidid>https://orcid.org/0000-0001-5600-2361</orcidid><orcidid>https://orcid.org/0000-0001-6979-5655</orcidid></search><sort><creationdate>20210127</creationdate><title>COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population</title><author>Garzon-Chavez, Daniel ; Rivas-Condo, Jackson ; Echeverria, Adriana ; Mozo, Jhoanna ; Quentin, Emmanuelle ; Reyes, Jorge ; Teran, Enrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-7aa62450cf92fb9bde119e912410d04cda15c3382daaa13e56b566c0e7e9660d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Amino acids</topic><topic>Bacillus Calmette-Guerin vaccine</topic><topic>BCG</topic><topic>BCG vaccine</topic><topic>BCG vaccine coverage</topic><topic>Chi-square test</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytokines</topic><topic>Disease transmission</topic><topic>Ecuador</topic><topic>Epigenetics</topic><topic>Geographic information systems</topic><topic>Granulocytes</topic><topic>Homology</topic><topic>Mathematical models</topic><topic>Pandemics</topic><topic>Provinces</topic><topic>Regions</topic><topic>Remote sensing</topic><topic>Sequences</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Statistical tests</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garzon-Chavez, Daniel</creatorcontrib><creatorcontrib>Rivas-Condo, Jackson</creatorcontrib><creatorcontrib>Echeverria, Adriana</creatorcontrib><creatorcontrib>Mozo, Jhoanna</creatorcontrib><creatorcontrib>Quentin, Emmanuelle</creatorcontrib><creatorcontrib>Reyes, Jorge</creatorcontrib><creatorcontrib>Teran, Enrique</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Vaccines (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garzon-Chavez, Daniel</au><au>Rivas-Condo, Jackson</au><au>Echeverria, Adriana</au><au>Mozo, Jhoanna</au><au>Quentin, Emmanuelle</au><au>Reyes, Jorge</au><au>Teran, Enrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population</atitle><jtitle>Vaccines (Basel)</jtitle><addtitle>Vaccines (Basel)</addtitle><date>2021-01-27</date><risdate>2021</risdate><volume>9</volume><issue>2</issue><spage>91</spage><pages>91-</pages><issn>2076-393X</issn><eissn>2076-393X</eissn><abstract>The Bacillus Calmette-Guérin (BCG) is a well-known vaccine with almost a century of use, with the apparent capability to improve cytokine production and epigenetics changes that could develop a better response to pathogens. It has been postulated that BCG protection against SARS-CoV-2 has a potential role in the pandemic, through the presence of homologous amino acid sequences. To identify a possible link between BCG vaccination coverage and COVID-19 cases, we used official epidemic data and Ecuadorian Ministry of Health and Pan American Health Organization vaccination information. BCG information before 1979 was available only at a national level. Therefore, projections based on the last 20 years were performed, to compare by specific geographic units. We used a Mann-Kendall test to identify BCG coverage variations, and mapping was conducted with a free geographic information system (QGIS). Nine provinces where BCG vaccine coverage was lower than 74.25% show a significant statistical association (χ Pearson's = 4.800, df = 1, = 0.028), with a higher prevalence of cases for people aged 50 to 64 years than in younger people aged 20 to 49 years. Despite the availability of BCG vaccination data and the mathematical models needed to compare these data with COVID-19 cases, our results show that, in geographic areas where BCG coverage was low, 50% presented a high prevalence of COVID-19 cases that were young; thus, low-coverage years were more affected.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33513693</pmid><doi>10.3390/vaccines9020091</doi><orcidid>https://orcid.org/0000-0002-5215-164X</orcidid><orcidid>https://orcid.org/0000-0001-5600-2361</orcidid><orcidid>https://orcid.org/0000-0001-6979-5655</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2076-393X
ispartof Vaccines (Basel), 2021-01, Vol.9 (2), p.91
issn 2076-393X
2076-393X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2bd651de822b4603b280ee90deb85938
source Publicly Available Content (ProQuest); PubMed Central
subjects Age
Amino acids
Bacillus Calmette-Guerin vaccine
BCG
BCG vaccine
BCG vaccine coverage
Chi-square test
Coronaviruses
COVID-19
Cytokines
Disease transmission
Ecuador
Epigenetics
Geographic information systems
Granulocytes
Homology
Mathematical models
Pandemics
Provinces
Regions
Remote sensing
Sequences
Severe acute respiratory syndrome coronavirus 2
Statistical analysis
Statistical tests
Vaccination
Vaccines
Viral diseases
title COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A20%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20Infection%20and%20Previous%20BCG%20Vaccination%20Coverage%20in%20the%20Ecuadorian%20Population&rft.jtitle=Vaccines%20(Basel)&rft.au=Garzon-Chavez,%20Daniel&rft.date=2021-01-27&rft.volume=9&rft.issue=2&rft.spage=91&rft.pages=91-&rft.issn=2076-393X&rft.eissn=2076-393X&rft_id=info:doi/10.3390/vaccines9020091&rft_dat=%3Cproquest_doaj_%3E2484212039%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c487t-7aa62450cf92fb9bde119e912410d04cda15c3382daaa13e56b566c0e7e9660d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2484212039&rft_id=info:pmid/33513693&rfr_iscdi=true